A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications

A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications

Bo Ding,1 Mark Small,2 Ulf Holmgren3 1Medical Evidence and Observational Research, AstraZeneca Gothenburg, Mölndal, Sweden; 2Real World Research (Respiratory), Adelphi Real World, Bollington, UK; 3Global Payer Evidence and Pricing, AstraZeneca Gothenburg, Mölndal, Sweden Backgrou...

Full description

Bibliographic Details
Main Authors:	Ding B, Small M, Holmgren U
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-05-01
Series:	International Journal of COPD
Subjects:	bronchodilators COPD treatment GOLD group symptom routine care
Online Access:	https://www.dovepress.com/a-cross-sectional-survey-of-current-treatment-and-symptom-burden-of-pa-peer-reviewed-article-COPD

Similar Items

COPD symptom burden: impact on health care resource utilization, and work and activity impairment
by: Ding B, et al.
Published: (2017-02-01)

Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma–COPD overlap syndrome consulting for routine care
by: Ding B, et al.
Published: (2018-03-01)

GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap
by: Roman-Rodriguez M, et al.
Published: (2021-06-01)

Economic Burden of COPD by Disease Severity – A Nationwide Cohort Study in Denmark
by: Løkke A, et al.
Published: (2021-03-01)

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study
by: Riju Ray, et al.
Published: (2019-08-01)

Functional performance in patients with COPD: association with treatment regimen, GOLD group, lung function, and symptom burden in a cross-sectional study
by: Ding B, et al.
Published: (2018-09-01)

When is dual bronchodilation indicated in COPD?
by: Thomas M, et al.
Published: (2017-08-01)

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis
by: Fabiano Di Marco, et al.
Published: (2018-01-01)

Exacerbations of COPD
by: Pavord ID, et al.
Published: (2016-02-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

[Acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD)]
by: Domenico Lorenzo Urso
Published: (2017-07-01)

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
by: Ferguson GT, et al.
Published: (2016-10-01)

Pharmacological Treatment in Asthma and COPD
by: Tomoaki Hoshino, et al.
Published: (2009-01-01)

Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry
by: Kobayashi S, et al.
Published: (2018-12-01)

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014
by: Josefin Sundh, et al.
Published: (2017-01-01)

A cross-sectional survey of night-time symptoms and impact of sleep disturbance on symptoms and health status in patients with COPD
by: Ding B, et al.
Published: (2017-02-01)

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
by: Singh S, et al.
Published: (2018-01-01)

ACO (Asthma–COPD Overlap) Is Independent from COPD: The Case Against
by: Peter M. A. Calverley, et al.
Published: (2021-06-01)

Frequency and Factors of Tremor, Palpitation, and Cramp in Patients with COPD and Asthma
by: Sema Demir, et al.
Published: (2015-04-01)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
by: Ichinose M, et al.
Published: (2016-08-01)

Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis
by: Nilsson Peter M, et al.
Published: (2005-08-01)

Comparative studies of dual bronchodilation in COPD
by: Mario Cazzola, et al.
Published: (2021-02-01)

Do patients and carers agree on symptom burden in advanced COPD?
by: Mi E, et al.
Published: (2018-03-01)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
by: Bishwakarma R, et al.
Published: (2017-01-01)

Prevention of copd exacerbations. Focus on dual bronchodilators
by: V. V. Arkhipov
Published: (2018-10-01)

The Importance of Inhaler Adherence to Prevent COPD Exacerbations
by: Jose R. Jardim, et al.
Published: (2019-04-01)

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
by: F. Maltais, et al.
Published: (2020-10-01)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies
by: Ohar JA, et al.
Published: (2019-02-01)

Global initiative gold and national recommendations on the management of patients with chronic obstructive pulmonary disease (COPD): the place of double bronchodilation
by: A. A. Vizel, et al.
Published: (2019-12-01)

Importance of the relationship between symptoms and self-reported physical activity level in stable COPD based on the results from the SPACE study
by: Florin Mihaltan, et al.
Published: (2019-05-01)

Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data
by: Müller V, et al.
Published: (2016-01-01)

A cross-sectional assessment of the burden of COPD symptoms in the US and Europe using the National Health and Wellness Survey
by: Ding B, et al.
Published: (2017-02-01)

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
by: Beth Hahn, et al.
Published: (2019-08-01)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
by: Beth Hahn, et al.
Published: (2019-04-01)

Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness
by: Chen C, et al.
Published: (2016-10-01)

Variation in Assignment of the COPD Patients into a GOLD Group According to Symptoms Severity
by: Moya-Álvarez V, et al.
Published: (2020-08-01)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
by: Gong S, et al.
Published: (2021-02-01)

Do 'guidelines' really guide us?
by: Milićević-Nešić Ivana J.
Published: (2017-01-01)

Symptomatic burden of COPD for patients receiving dual or triple therapy
by: Chen S, et al.
Published: (2018-04-01)